Contracts › HDTRA123C0009
HDTRA123C0009: Optimization and Production of Single-Shot Vaccines for Melioidosis and Glanders
Awarded to Vitrivax, Inc. by Defense Threat Reduction Agency.
$14.5Mobligated
$29.8Mpotential value
11 February 2027current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | HDTRA123C0009 |
|---|---|
| Awardee | Vitrivax, Inc. |
| Awarding agency | Defense Threat Reduction Agency |
| Awarding office | DEFENSE THREAT REDUCTION AGENCY |
| NAICS | 541715 Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) |
| PSC | AC33 National Defense R&D Services; Defense-Related Activities; Experimental Development |
| Place of performance | CO |
| Offers received | 1 |
| Period of performance | 12 January 2023 to 11 February 2027 |
| Potential end | 11 January 2028 |
| Estimated recompete solicitation | Now / imminent (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 03 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541715 contracts · All expiring contracts · USASpending record